None listed
Conditions
Interventions
Biological/Vaccine, Non-Stem Cell : The study schedule selected patients with stable disease or response according to RECIST version 1.1 after completing 4 cycles of ACE chemoimmuno therapy before t
Sponsors
Chonnam National University Hospital Hwasun Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who are histologically or cytologically confirmed to have extensive stage small cell lung cancer. 2) Patients with no tumor progression observed after 4 cycles of the first-line chemoimmunotherapy (ACE regimen) 3) an adult over the age of 19 4) Patients with ECOG performance score below 2 5) Patients who have signed and agreed to participate in this clinical study 6) A patient who has obtained a consent form for donation to the Biobank of Chonnam National University Hwasun Hospital 7) Patients who meet the following conditions in a blood test. - Absolute neutrophil count (ANC) = 1.0 x 10^9/L - White blood cells count (WBC) = 3.0 x 10^9/L - Serum bilirubin = 2.5 x Normal range - AST and ALT = 2.5 × Normal Range
Exclusion criteria
Exclusion criteria: 1) Patients who are not histologically or cytologically small cell lung cancer 2) Patients observed progression of disease after 2 cycles of first-line chemoimmunotherapy (ACE regimen) 3) Patients who have not completed primary ACE regimen up to 4 cycles 4) Untreated active brain or central nervous system metastasis 5) Uncontrolled cardiovascular disease (e.g., myocardial infarction and unstable angina within 3 months) 6) an uncontrolled, active infectious disease 7) a patient with autoimmune disease 8) Pregnant women, lactating women, or pregnant women who do not use proper contraception.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival | — |
Countries
Korea, Republic of
Contacts
Public ContactIn-Jae Oh
Chonnam National University Hospital Hwasun Hospital
Outcome results
None listed